Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/1999
12/14/1999US6001331 Introducing into patient benzylthiazol-3-ium derivatives of given formula; allowing time for compound to associate with amyloid; detecting the labeled compound associated with amyloid deposits
12/14/1999CA2180334C Coprocessed galactomannan - glucomannan
12/14/1999CA2135642C Tat-derived transport polypeptides
12/14/1999CA2074503C Pharmaceutical formulation containing penciclovir
12/14/1999CA2046830C Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
12/09/1999WO1999062983A1 Polyethylene glycol-polyorthoester, polyethylene glycol-polyorthoester-polythylene glycol, and polyorthoester-polyethylene glycol-polyorthoester block copolymers
12/09/1999WO1999062958A1 Acylated alkylated cyclodextrin derivatives and their use as carriers for medicaments
12/09/1999WO1999062923A2 Immunostimulatory oligonucleotides with modified bases and methods of use thereof
12/09/1999WO1999062564A1 Radioiodinated phenols for brachytherapy
12/09/1999WO1999062560A1 Stabilization of compositions containing ace inhibitors using magnesium oxide
12/09/1999WO1999062557A1 Composition for the transdermal administration of non-steroidal anti-inflammatory drugs
12/09/1999WO1999062551A1 Texaphyrin conjugates and uses thereof
12/09/1999WO1999062546A1 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
12/09/1999WO1999062536A2 Pharmaceutical formulations for igf/igfbp
12/09/1999WO1999062535A2 Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
12/09/1999WO1999062528A1 Treatment of arthritis and other similar conditions
12/09/1999WO1999062526A2 Use of genetically engineered antibodies to cd38 to treat multiple myeloma
12/09/1999WO1999062519A1 Semi-solid aqueous preparations for oral applications of toltrazuril sulphone
12/09/1999WO1999062516A1 A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer
12/09/1999WO1999062510A2 Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
12/09/1999WO1999062503A2 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
12/09/1999WO1999062500A1 Stabilizers for lyophilized vaccines
12/09/1999WO1999062498A1 Spill resistant pharmaceutical compositions
12/09/1999WO1999062497A1 Stable gel mixture in the form of a mixture of oleogel and aqueous gel
12/09/1999WO1999062496A1 Methods and devices for providing prolonged drug therapy
12/09/1999WO1999062463A1 α-HYDROXY FATTY ACID DERIVATIVES AND COMPOSITION FOR EXTERNAL USE CONTAINING THE SAME
12/09/1999WO1999047176A3 Latent reactive blood compatible agents
12/09/1999WO1999038528A3 Vaccine formulations
12/09/1999WO1999032152A3 Methods for delivering pharmaceutical agents to mucosal surfaces
12/09/1999WO1999024066A3 Methods and compositions for enhancing immune response and for the production of in vitro mabs
12/09/1999DE19824483A1 Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon Semi-solid aqueous preparations for oral administration of toltrazuril sulfone
12/09/1999CA2334809A1 Texaphyrin conjugates and uses thereof
12/09/1999CA2333688A1 Methods and devices for providing prolonged drug therapy
12/09/1999CA2333661A1 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
12/09/1999CA2333505A1 Stabilizers for lyophilized vaccines
12/09/1999CA2332333A1 Peg-poe, peg-poe-peg, and poe-peg-poe block copolymers
12/09/1999CA2330581A1 Stabilization of compositions containing ace inhibitors using magnesium oxide
12/09/1999CA2330225A1 Immunostimulatory oligonucleotides with modified bases and methods of use thereof
12/09/1999CA2329940A1 Use of genetically engineered antibodies to cd38 to treat multiple myeloma
12/08/1999EP0961794A1 Transdermal pressure sensitive adhesive drug delivery system and pressure sensitive adhesive used therein
12/08/1999EP0961793A1 Polymers incorporating peptides
12/08/1999EP0961783A1 Polysaccharide conjugates of biomolecules
12/08/1999EP0961619A1 Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
12/08/1999EP0961612A1 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
12/08/1999EP0824545B1 Peptide compositions with growth factor-like activity
12/08/1999EP0807127B1 Method of preparing low-viscosity cationic biopolymers
12/08/1999EP0606280B1 New conjugates for the introduction of nucleic acid into higher eukaryotic cells
12/08/1999CN1237908A Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
12/08/1999CN1237907A Formulation for electrically assisted delivery of lidocaine and epinephrine
12/08/1999CN1237903A Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules
12/08/1999CN1237902A Method for producing shaped and unshaped polyol masses
12/08/1999CN1237901A Protein stabilized pharmacologically active agents, methods for preparation thereof and methods for use thereof
12/08/1999CN1237417A Controlled drug delivery system for diltiazem
12/08/1999CN1237407A Lip-protecting composition containing acetohexylamic acid and its use
12/08/1999CN1047076C Stabilized injection and method of stabilizing injection
12/08/1999CN1047075C Bisacodyl dosage form
12/07/1999US5998603 4'-desmethyl nucleoside analogs, and oligomers thereof
12/07/1999US5998598 Immunoadhesins and methods of production and use thereof
12/07/1999US5998588 Interactive molecular conjugates
12/07/1999US5998587 Anti-cyanovirin antibody
12/07/1999US5998488 Prevent adsorption of microbiocides by contact lenses; mixture containing boric acid, ethylenediamine and a cyclodextrin
12/07/1999US5998480 Pharmaceutical preparation containing nimesulide for topical use
12/07/1999US5998430 Bladder and urinary system disorders
12/07/1999US5998418 Enrofloxacine injection or infusion solutions
12/07/1999US5998397 Gallium complexes of 3-Hydroxy-4-pyrones to treat or prevent bone disease
12/07/1999US5998392 Benzoyl peroxide flocculent materials and methods of their preparation
12/07/1999US5998365 Solvent system comprising a hydrophilic component, a hydrophobic component, and a surfactant, wherein the hydrophilic component is propylene carbonate or polyethylene glycol having average molecular weight of less than 1000.
12/07/1999US5998216 Stabilizing formulation for preserving the integrity of proteins present in a body fluid sampled ex-vivo for evaluation as a specimen
12/07/1999US5998192 For use in many human gene therapy protocols, especially those requiring transduction of normal or neoplastic haemopoietic cells.
12/07/1999US5998140 Complexes of cell with oligomer
12/07/1999US5997905 Preparation of pharmaceutically active particles
12/07/1999US5997904 Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
12/07/1999US5997903 Oral-administration forms of a medicament containing pantoprazol
12/07/1999US5997899 Method for producing liposomes with increased percent of compound encapsulated
12/07/1999US5997898 Stabilized compositions of a sf6 gas and a phosphorylated fluorinated amphiphilic compound, contrast agents for ultrasound.
12/07/1999US5997885 Cosmetic and/or dermatological composition containing thermal spring water or mineral water and an active agent, in order to combat acne or aging
12/07/1999US5997861 Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
12/07/1999US5997856 Il-2 and an effective formulating amount of a substituted cyclodextrin
12/07/1999US5997848 Methods and compositions for pulmonary delivery of insulin
12/07/1999US5997610 Amphiphilic compounds with at least two hydrophilic and at least two hydrophobic groups based on dicarboxylic acid diamides
12/07/1999CA2192687C Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
12/07/1999CA2162248C Liquid antacid compositions
12/07/1999CA2161103C Controlled release oxybutynin formulations
12/07/1999CA2157410C Enhanced circulation effector composition and method
12/07/1999CA2103793C Solvent system to be enclosed in capsules
12/07/1999CA2002552C Pharmaceutical aqueous solution for ophthalmic use comprising a water solube pharmaceutically acceptable acid addition salt of ibopamine
12/07/1999CA2000744C Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
12/02/1999WO1999062079A1 Nucleation and growth of magnetic metal oxide nanoparticles and its use
12/02/1999WO1999061593A1 USE OF MODIFIED LYSOZYME c TO PREPARE MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES
12/02/1999WO1999061512A1 Polyamino acid vesicles
12/02/1999WO1999061481A1 Amphiphilic polysaccharide derivatives
12/02/1999WO1999061097A2 Alpha emitting constructs and uses thereof
12/02/1999WO1999061066A2 Convection-enhanced delivery of aav vectors
12/02/1999WO1999061062A1 Cyclodextrin complexes
12/02/1999WO1999061061A1 Drug composites
12/02/1999WO1999061060A1 Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy
12/02/1999WO1999061055A1 Bifunctional molecules and therapies based thereon
12/02/1999WO1999061047A1 Compound delivery using rapidly dissolving collagen film
12/02/1999WO1999061031A1 Treatment of c. difficile toxin b associated conditions
12/02/1999WO1999061025A1 Microemulsion preconcentrates containing a piperidine substance p antagonist
1 ... 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 ... 1712